 |
|
|
|||||
Unlocking the power of genetics to provide meaningful answers to patients when they matter most is at the crux of precision diagnostics. As technologies advance, costs fall, and evidence builds, genomic sequencing has great potential to transform the trajectory of patient care. It will do so by shortening the diagnostic odyssey. It will guide and speed up more personalized and effective treatment decisions. And it will improve patient outcomes more than ever before. For innovation to truly scale, it will require deep collaboration and seamless integration across the healthcare ecosystem. BUILD A STRONGER PARTNERSHIP ECOSYSTEM Making genomic sequencing a standard practice in patient care at scale is not something any organization can accomplish alone. It requires coordinated efforts from providers who identify the clinical need and offer it to patients, as well as health systems integrating testing into care pathways. It also depends on clinical societies broadening their guidelines to include these recommendations, payers expanding access through coverage decisions, and industry partners bringing innovative technologies to the table. These collaborations create the synergies necessary to advance genomics from a specialty tool to a standard-of-care approach. Working together, we can help ensure that patients across diverse populations benefit from advances in precision diagnostics. This partnership-driven approach also accelerates the translation of genomic findings into clinical action. When clinicians, lab partners, and digital health platforms work together, the pathway from sample collection to diagnosis becomes more streamlined. Patients ultimately see faster, more actionable results. In a rapidly evolving field like genomics, this type of collaboration is key. APPROACH CARE THROUGH A COMPREHENSIVE MULTIOMIC LENS Genetic testing has traditionally involved assessing just the DNA for changes that might cause disease. More recently, a multiomic approach to care that involves looking at data from other omics has been pursued. These include transcriptomics, metabolomics, and methylomics. By layering these and other datasets, multiomics can provide a dynamic, functional view that can reveal disease mechanisms beyond a DNA test alone. Incorporating multiomic data can make all the difference in complex rare diseases and inherited conditions where a diagnosis is otherwise elusive. The powerful impact of a multiomic approach is best illustrated using a real-world case. Reed was just 18 months old when his parents, Kelly and Chris, began noticing differences in his development, including delays in speech and motor skills, as well as involuntary movements. What followed were years spent navigating waiting rooms, specialist appointments, and numerous tests that offered few clear answers, making it difficult to make informed decisions about his care. It was not until the family pursued whole genome sequencing (WGS), followed by RNA-seq, that they gained meaningful insight into a possible underlying contributor. WGS identified a variant in the FOXP4 gene, which is known to play a role in regulating other genes involved in brain development, speech, and motor coordination. To better understand the functional impact of this variant, RNA-seq was performed and demonstrated abnormal splicing associated with the FOXP4 variant, supporting its classification as likely pathogenic. While this finding did not explain all of Reeds medical and developmental challenges, it provided important biological context and helped clarify one significant factor contributing to his clinical picture. The combination of WGS and RNA-seq marked a turning point for the family, enabling more informed discussions with clinicians and supporting a more precise, individualized approach to Reeds ongoing care. INNOVATION STARTS BEHIND THE SCENES The true potential of precision diagnostics cant be unlocked without meticulously designed workflows that support each sample from order to result. These behind-the-scenes capabilities are what allow innovation to scale responsibly, and what ensures that patients and providers receive accurate, timely, and clinically actionable answers. Flexible sample collection options give providers the ability to serve patients where they are, whether in clinics, hospitals, mobile settings, or at home. This flexibility reduces barriers to testing and helps broaden access for patients who may face logistical challenges. Automated processing and high-throughput systems ensure that every sample moves through the lab with consistent quality and efficiency. This allows organizations to handle increasing test volumes without compromising accuracy or turnaround time. This is an essential capability as more health systems adopt genomic testing at scale. Finally, seamless electronic health record integration ensures that results flow directly into clinical workflows, making it easier for providers to interpret genomic data and act on it quickly. When clinicians have access to clear, well-structured reports within their existing systems, genomic testing becomes a natural part of patient care. Together, these operational strengths form the backbone of a world-class customer experience that will make precision diagnostics truly scalable. Kengo Takishima is chairman and CEO of Baylor Genetics.
Category:
E-Commerce
Warner Bros. Discovery says it’s reviewing a new takeover offer from Paramount, but it continues to recommend a competing proposal from Netflix to its shareholders in the meantime. Warner disclosed Tuesday that it had received a revised offer from Paramount after a seven-day window to renew talks with the Skydance-owned company elapsed Monday. Paramount confirmed it had submitted this proposal, but neither provided further details on the bid. The company was widely expected to have raised its offer. A Warner Bros. Discovery buyout would reshape Hollywood and the wider media landscape bringing HBO Max, cult-favorite titles like Harry Potter and, depending on who wins the Netflix v. Paramount tug-of-war, potentially even CNN under a new roof. Paramount wants to acquire Warner Bros. in its entirety including networks like CNN and Discovery and went straight to shareholders with an all-cash, $77.9 billion hostile offer just days after the Netflix deal was announced in December. Accounting for debt, that bid offered Warner stakeholders $30 per share, amounting to an enterprise value of around $108 billion. Paramount maintained on Tuesday that its tender offer remains on the table while Warner evaluates its latest proposal. Netflix only wants to buy Warners studio and streaming business for $72 billion in cash, or about $83 billion including debt. Warners board has repeatedly backed this deal and on Tuesday maintained that its agreement with Netflix still stands. A press contact for Netflix did not immediately respond to a request for comment. Warner shareholders are set to vote on the Netflix proposal on March 20. If Warner’s board changes course and deems Paramount’s latest offer superior, Netflix would have a chance to match or revise its proposal, potentially setting the stage for a fresh bidding war. It could also choose to walk away. Paramount, Warner and Netflix have spent the last couple of months in a heated back and forth over who has a stronger deal. But many lawmakers and entertainment trade groups have sounded the alarm along the way, warning that either buyout of all or parts of Warners business would only further consolidate power in an industry already run by just a few major players. Critics say that could result in job losses, less diversity in filmmaking and potentially more headaches for consumers who are facing rising costs of streaming subscriptions as is. Combined, that raises tremendous antitrust concerns and a Warner sale could come down to who gets the regulatory greenlight. The U.S. Department of Justice has already initiated reviews, and other countries are expected to do so. Both Paramount and Netflix have argued that their proposals are good for consumers and the wider industry. And the companies have taken aim at each other publicly with regulatory arguments. Paramount has pointed to Netflix’s much larger market value. And it’s argued that if the streaming giant acquires Warner, it would only give it more dominance in the subscription video on demand space. But Netflix is trying to convince regulators that its up against broader video libraries, particularly Google’s YouTube. Netflix has also said that since it doesnt currently have the same studios and film distribution that Warner does, it would preserve and grow those operations whereas a Warner-Paramount merger would combine two of Hollywoods last five major studios, as well as theatrical channels and news networks. Politics could also come into play. President Donald Trump previously made unprecedented suggestions about his involvement in seeing a deal through, before walking back those statements and maintaining that regulatory approval will be up to the Justice Department. Trump has a close relationship with the billionaire Oracle founder Larry Ellison (the father of Paramount Skydance CEO David Ellison) who is heavily backing Paramount’s bid to buy Warner. And the push to acquire Warner arrive just months after Skydance closed its own buyout of Paramount in a contentious merger approved just weeks after the company agreed to pay the president $16 million to settle a lawsuit over editing at Paramount’s 60 Minutes program on CBS. Under new ownership, CBS has seen significant editorial shifts, notably with the installation of Free Press founder Bari Weiss as editor-in-chief of CBS News. Critics say similar changes could happen at Warner’s CNN if Paramount’s bid is successful. But Trump has continued to publicly lash out at Paramount over editorial decisions at CBS 60 Minutes. The president also previously met with Netflix co-CEO Ted Sarandos, who he called a fantastic man. Wyatte Grantham-Philips, AP business writer
Category:
E-Commerce
Eight times the output. Same job. Same title. Not 80%. 800%. Thats a lot. And yet, most hiring systems and processes are almost perfectly designed to miss those people. This isnt a talent shortage. Weve normalized a measurement problem for so long that it barely registers as a problem anymore. Across industries, hiring has been optimized for efficiency and familiarity. We screen for credentials that look impressive, resumes that read cleanly, and career paths that resemble the ones we already trust. It feels rigorous. It feels fair. But it isnt actually predictive of performance. In fact, the more polished a hiring process becomes, the more likely it is to filter for samenessand against the very capabilities that drive outsized performance. Much of this starts with technology that was designed for process automation and then tried to evolve to deliver objectivity at scale. Keyword-based applicant tracking systems move fast, but speed comes at a cost. These systems reward precise phrasing and conventional formatting, not capability. A candidate who has done the workbut describes it differentlynever makes it through. These systems werent built for filtering talent inthey were built to filter talent out. Manual review is often held up as the antidote, but it brings its own limitations. Humans are better at nuance, but were also deeply patterned. The 3-pound caloric monsters we carry around in our skulls are designed for pattern recognition and the path of least resistance. By genetics, we gravitate toward what looks familiar and overvalue signals that feel safe. And even when intentions are good, unstructured evaluation consistently misses qualified candidateswhile remaining impossible to scale. And then, the elephant in the room: Teams are really stretched. Thoughtful, consistent, manual review is less and less feasible, leaving organizations stuck in an uncomfortable middle. Do we settle for technology that is efficient but blind, or humans who are thoughtful but inconsistent? Neither reliably captures what actually predicts performance. DISTANCE TRAVELED This isnt a new problem. Two decades ago, medical schools ran into the same issue. Traditional admissions criteriagrades, test scores, pedigreewere effective at predicting who could pass exams. They were far less effective at predicting who would become exceptional physicians. The metrics were clean. The outcomes were not. So some institutions started asking different questions. Not just How did this person perform? but How far did they travel to get here? What obstacles did they face? What did they have to figure out without a playbook? This ideaoften referred to as distance traveledimpacted who was admitted. And it changed outcomes for the better. Students selected under these frameworks didnt just keep upthey set the bar. They demonstrated stronger judgment under pressure, greater adaptability in ambiguous situations, and deeper empathy with patients whose lives looked nothing like their own. Corporate hiring is now facing a similar time in history, a convergence of inflection points. In fast-moving business environments, the skills that matter most rarely show up neatly in job titles or degrees: learning quickly; thinking clearly when information is incomplete; staying resourceful when plans fall apart; persisting when theres no obvious path forward. These arent soft skills. Theyre critical performance and leadership skills and theyre largely invisible in traditional screening. And thats bad. Its bad for innovation, its bad for culture, its bad for the bottom line. The cost of getting this wrong shows up everywhere. Most employers will admit theyve made at least one bad hire in the past year. The financial impact of that is relatively easy to calculate. The less visible damagelost momentum, exhausted teams, opportunities that never materializeis harder to measure, but no less real. Whats even harder to see or measure is the impact of the lost talent that never had a chance to contribute. The career changer who learned fast because they had to. The veteran who led teams under pressure but doesnt speak corporate. The self-taught professional who mastered complex systems without a credential to legitimize it. These candidates have already demonstrated the capabilities companies say they want, but they dont look as shiny on paper. CHANGE WHAT YOU MEASURE All is not lost. Some organizations are starting to respondnot by lowering standards, but by changing what they measure. Instead of defaulting to credentials and pedigree, theyre evaluating skills directly. Theyre using assessment questions about real-world scenarios, samples, or actual work, and problem-solving exercises that reflect the actual demands of the role. The shift is delivering significant organizational impact. Research shows that when hiring is grounded in capability rather than convention, candidate pools widen. Quality improves. Competition for the same narrow band of perfect resumes eases. But the real advantage runs deeper than these metrics. CAN COMPANIES AFFORD NOT TO EVOLVE? Traditional hiring was built for a world where careers were linear and jobs changed slowly. In that world, past experience was a reasonable proxy for future performance. That world is gone! Today, the defining advantage isnt what someone already knowsits how quickly they can learn what comes next. Medical schools recognized this years ago. They stopped over-indexing on metrics that predicted short-term success and started evaluating for the human capabilities that predict excellence over time. The corporate world needs to catch up. The question for CEOs and CHROs isnt whether hiring should evolve. Its whether organizations can afford not to evolve and to just leave enormous performance upside untouched. Because somewhere in your applicant pool is a candidate who figured things out the hard way or who learned faster because they had fewer options. Someone who developed exactly the capabilities your business needs next. Your systems may never notice them, but someone elses will. Natasha Nuytten is CEO of CLARA.
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||